Inhibrx Biosciences Shares Exciting Trial Results for Ozekibart
Inhibrx Biosciences, Inc. (Nasdaq: INBX), a biopharmaceutical company dedicated to innovative cancer treatments, recently shared promising preliminary data from the Phase 1 trial of ozekibart (INBRX-109). This groundbreaking treatment is being investigated in combination with FOLFIRI for patients battling advanced or metastatic, unresectable colorectal adenocarcinoma (CRC). The results were presented at a prominent oncology symposium, highlighting the potential impact of ozekibart on patient care.
Encouraging Efficacy Results
The efficacy of ozekibart was evaluated in a study involving 10 of the 13 patients who had received at least one dose. The outcomes were determined using the RECIST v1.1 criteria. The findings were impressive: one patient experienced a complete response (CR), three had partial responses (PR), and six maintained stable disease (SD). Notably, a substantial portion—46.2% of the patients—achieved durable disease control lasting over 180 days. Moreover, the median progression-free survival (PFS) was recorded at 7.85 months.
The Patient Journey
All trial participants had undergone at least one prior line of systemic therapy, with a median of two therapies previously administered. It is worth highlighting that the individual who attained a complete response had previously been treated with three different lines of therapy. Additionally, the partial responses were noted in patients who had not found success with previous FOLFIRI-based treatments, showcasing the potential of ozekibart for those with limited options.
Safety Profile of Ozekibart
In terms of safety, treatment-emergent adverse events (TEAEs) were reported in 84.6% of the participants. Most of these events were of mild to moderate severity, with grade 1 or 2 effects being the most common. However, grade ?3 TEAEs occurred in 30.8% of patients, indicating that while there may be risks, the majority of adverse events were manageable. Common side effects included nausea, elevated alanine aminotransferase, diarrhea, and fatigue, predominantly classified as low-grade.
Next Steps for Ozekibart
Encouraged by these results, Inhibrx is moving forward by initiating an expansion cohort aimed at confirming these preliminary findings. This new group of up to 50 patients will consist of individuals who have had two to three prior lines of systemic therapy, and the company expects to launch data analysis in the third quarter of 2025. Their strategy reflects a commitment to refining treatment options for challenging cancer cases.
Understanding Colorectal Adenocarcinoma
Colorectal adenocarcinoma stands as the third most common cancer worldwide and is a leading cause of cancer-related mortality. According to recent data, around 2 million new cases of CRC emerged globally in 2020, claiming nearly 1 million lives. The need for effective therapies beyond the second-line treatment options remains critical, as highlighted by a discouraging five-year relative survival rate of just 15.7% for patients with metastatic CRC in the U.S.
The Role of Ozekibart (INBRX-109)
Ozekibart represents a significant advancement in cancer therapy. This uniquely engineered tetravalent death receptor 5 (DR5) agonist antibody aims to harness the tumor-directed cell death triggered by DR5 activation. Its approval journey has been marked by achievements like receiving Fast Track designation from the FDA for treating metastatic or unresectable conventional chondrosarcoma and an orphan drug designation for the same condition.
Furthermore, Inhibrx is conducting a Phase 2 trial, which is randomized and placebo-controlled, to assess ozekibart's efficacy in individuals with metastatic, unresectable conventional chondrosarcoma. This trial is ongoing and anticipated to provide results in the near future, adding another layer to the excitement surrounding the development of this therapeutic candidate.
About Inhibrx Biosciences, Inc.
Inhibrx Biosciences is a pioneering biopharmaceutical company focused on developing a diverse range of biologic therapeutic candidates. They leverage advanced protein engineering techniques to address the complex biology associated with various diseases. Formally established as a subsidiary of Inhibrx, Inc. in early 2024, the company remains dedicated to innovative therapeutic solutions. Its clinical pipeline includes both ozekibart (INBRX-109) and INBRX-106, with key data readouts anticipated in the coming years.
Frequently Asked Questions
What are the key findings from the Phase 1 trial of ozekibart?
The trial demonstrated notable efficacy with one complete response, three partial responses, and a median progression-free survival of 7.85 months.
What types of adverse events were reported during the trial?
Most adverse events were mild, with common issues like nausea and fatigue observed. Grade ?3 TEAEs occurred in 30.8% of patients.
How is Inhibrx proceeding after the preliminary results?
Inhibrx plans to initiate an expansion cohort study to validate findings in a more uniform patient population.
Why is colorectal adenocarcinoma significant?
It is the third most frequent cancer worldwide and has a low five-year survival rate, highlighting the need for better therapies.
What does ozekibart target?
Ozekibart targets death receptor 5 (DR5) activation to induce tumor-directed cell death, representing a promising advancement in cancer treatment.
